Paul Hastings LLP advised Leerink Partners as sole book running manager in connection with PepGen, Inc.,’s underwritten offering of 7,530,000 shares of common stock at $10.635 per share. The gross proceeds are expected to be approximately $80.1 million. PepGen, Inc., (Nasdaq: PEPG) is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases.

Partner and co-chair of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and Capital Markets partner Will Magioncalda led the Paul Hastings team, which included associates Chris Guerin and Adam Swank.

More details about the transaction can be found here. 

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.